Optimizing the synthesis of[18F]FTMP for commercial distribution

优化 [18F]FTMP 的合成以进行商业分销

基本信息

  • 批准号:
    10601199
  • 负责人:
  • 金额:
    $ 29.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-02-15 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

Abstract The development of genetic medicines such as gene and cell therapies like Chimeric Antigen Receptor (CAR) T cells has necessitated new technologies that can monitor the biodistribution of these therapies in human patients. Imaging is particularly well suited to provide such quantitative measurements of a genetic medicine over time. Vellum Biosciences is a platform imaging company geared to fill this void in technology, providing repeatable, robust, sensitive measures of a genetic medicine in situ with clear applications in new drug development, clinical research, and eventually clinical practice. Vellum’s technology is based on positron emission tomography (PET) radiotracer derivatives of the synthetic antibiotic trimethoprim (TMP) and its protein target dihydrofolate reductase (DHFR). When DHFR is expressed in a genetically delivered medicine (e.g. mRNA, lentiviral or adenoviral vectors), TMP radiotracers can be used to measure the expression of the protein products in any tissue within the body. This strategy has been used to monitor the trafficking of CAR T cells targeting several solid tumors in animals. In this STTR phase 1, we propose the development of a commercially viable radiosynthetic route for broad, widespread distribution of TMP radiotracers. In AIM1, we will develop a two-step radiosynthetic process which shall decrease the need for HPLC purification and co-develop a single vessel synthesis which will be applicable to many commercial radiosynthesis modules. In AIM2, we focus on a cartridge-based, solid-phase workup of the radiochemical products. Taken together these short-term goals provide both the feasibility and tractability for commercial radiopharmacy production of TMP radiotracers. More broadly, imaging is expected to be particularly important in the coming decades to validate and prioritize new genetic medicine therapies. We have already formed relationships with global pharmaceutical companies to use these technologies and envision that these approaches are critical to the advancement of next-generation medicines for the continued improvement of human health.
摘要 基因药物的发展,如基因和细胞疗法,如嵌合抗原受体(CAR) T细胞需要新的技术,可以监测这些疗法在人体内的生物分布 患者成像特别适合于提供遗传医学的这种定量测量 随着时间Vellum Biosciences是一家平台成像公司,旨在填补技术空白, 可重复的、稳健的、灵敏的原位遗传药物测量,在新药开发中具有明确的应用 发展,临床研究,最终临床实践。Vellum的技术是基于正电子 合成抗生素甲氧苄啶(TMP)及其蛋白质的发射断层扫描(PET)放射性示踪剂衍生物 靶向二氢叶酸还原酶(DHFR)。当DHFR在基因递送的药物中表达时(例如, mRNA、慢病毒或腺病毒载体),TMP放射性示踪剂可用于测量蛋白质的表达 产品在体内的任何组织。该策略已用于监测CAR T细胞的运输 靶向动物体内的几种实体瘤。在这个STTR第1阶段,我们建议开发一种商业化的 TMP放射性示踪剂广泛分布的可行的放射性合成途径。在AIM1中,我们将开发一个 两步放射合成工艺,这将减少对HPLC纯化的需求,并共同开发单一的 容器合成,其将适用于许多商业放射合成模块。在AIM2中,我们专注于 放射化学产物的固相后处理。把这些短期目标放在一起 为TMP放射性示踪剂的商业放射性药物生产提供了可行性和易处理性。更 总的来说,在未来几十年中,成像预计将特别重要,以验证和优先考虑新的 基因医学疗法我们已经与全球制药公司建立了关系, 这些技术,并设想这些方法是至关重要的下一代的进步, 药物,以持续改善人类健康。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mark A Sellmyer其他文献

Mark A Sellmyer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mark A Sellmyer', 18)}}的其他基金

Regulation of eDHFR-tagged proteins with trimethoprim PROTACs
使用甲氧苄啶 PROTAC 调节 eDHFR 标记蛋白
  • 批准号:
    10714294
  • 财政年份:
    2023
  • 资助金额:
    $ 29.99万
  • 项目类别:
Next generation tools for imaging bacterial infection and its relationship to the immune system
用于成像细菌感染及其与免疫系统关系的下一代工具
  • 批准号:
    10247494
  • 财政年份:
    2018
  • 资助金额:
    $ 29.99万
  • 项目类别:
Next generation tools for imaging bacterial infection and its relationship to the immune system
用于成像细菌感染及其与免疫系统关系的下一代工具
  • 批准号:
    10481833
  • 财政年份:
    2018
  • 资助金额:
    $ 29.99万
  • 项目类别:
Next generation tools for imaging bacterial infection and its relationship to the immune system
用于成像细菌感染及其与免疫系统关系的下一代工具
  • 批准号:
    10001362
  • 财政年份:
    2018
  • 资助金额:
    $ 29.99万
  • 项目类别:

相似海外基金

Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
  • 批准号:
    19K09482
  • 财政年份:
    2019
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
  • 批准号:
    2273599
  • 财政年份:
    2019
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
  • 批准号:
    18K14964
  • 财政年份:
    2018
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
  • 批准号:
    16K18873
  • 财政年份:
    2016
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
  • 批准号:
    9193681
  • 财政年份:
    2016
  • 资助金额:
    $ 29.99万
  • 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
  • 批准号:
    15K18939
  • 财政年份:
    2015
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
  • 批准号:
    26450450
  • 财政年份:
    2014
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
  • 批准号:
    26462183
  • 财政年份:
    2014
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
  • 批准号:
    26893253
  • 财政年份:
    2014
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
  • 批准号:
    24701021
  • 财政年份:
    2012
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了